OneAscent Healthcare

Fact Sheet: June 30th, 2025

OneAscent INVESTMENTS

INVESTMENT APPROACH

Combining OneAscent's values-based investing approach and Eventide's portfolio management insight, the strategy is actively managed and invested in equities of healthcare companies that are primarily within the biotechnology industry.

The strategy invests primarily in U.S. equities, with foreign exposure typically less than 10%. The size-weighted, average market cap range is typically $1-15 billion USD.

Stock selection is driven by Eventide's fundamental research and values-based criteria. Investment decisions may also take into account overall market conditions and trading volumes.

This strategy may be appropriate for investors seeking high absolute returns with low correlation to the market, but who are willing to tolerate higher volatility.

INVESTMENT OBJECTIVE
Long-term capital appreciation

TARGET HOLDINGS
40-70

BENCHMARK
NASDAQ Biotechnology Index

INVESTMENT MINIMUM
$50,000

MANAGEMENT FEE
0.70%

INVESTMENT PROCESS

- **Identify companies** with (1) strong fundamentals, (2) that create value for stakeholders, and (3) trade at attractive valuations.
- **Establish an investment case** based on fundamental analysis of the company's products or services, the industry in which it operates, sustainable competitive advantages, management team, and financials as well as research on how the company creates value for patients, doctors, the healthcare system, employees, society, the environment, and local communities. Valuation analysis is then performed to establish a price target as well as upside and downside valuation.
- **Evaluate the health of the market** by utilizing a three-legged stool approach to assess leading indicators, valuation measures, and investor sentiment.
- **Construct the portfolio** with appropriate industry and sector weightings informed by the level of macro risk. Determine position sizing based on conviction level and risk/reward profile.
- **Actively monitor holdings** to ensure that the investment thesis remains intact.

MANAGED BY



Finny Kuruvilla, MD, PhD

Portfolio Manager

Finny Kuruvilla serves as Chief Investment Officer and Portfolio Manager for Eventide Asset Management. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing.

Eventide Asset Management is an independently registered third party investment adviser and is not affiliated with OneAscent Investment Solutions.

EVENTIDE

TRAILING RETURNS

Inception Date: 3/29/2017

	3 Month	YTD	1 Year	3 Years	5 Years	Since Inception
OneAscent Healthcare	14.57	1.88	-1.26	11.46	-1.97	4.29
NASDAQ Biotechnology TR USD	-0.15	-1.46	-6.21	4.94	0.45	4.62

OneAscent Healthcare

Fact Sheet: June 30th, 2025

SECTOR ALLOCATION

	%
Healthcare	100.0
Total	100.0

MARKET RISK

	Std Dev	Alpha	Beta	R2	Sharpe
OneAscent Healthcare	26.28	-0.21	1.15	53.84	-0.06
NASDAQ Biotechnology TR USD	16.76	0.00	1.00	100.00	-0.07

ANNUAL RETURNS

	2017*	2020	2021	2022	2023	2024
OneAscent Healthcare	21.35	27.24	-19.54	-22.96	23.33	-11.36
NASDAQ Biotechnology TR USD	9.30	26.36	0.02	-10.13	4.60	-0.57

TOP HOLDINGS

Company	Ticker	Weight %
SPDR® Blmbg 1-3 Mth T-Bill ETF	BIL	7.33
Verona Pharma PLC ADR	VRNA	5.43
Insmed Inc	INSM	4.22
Guardant Health Inc	GH	4.17
Mirum Pharmaceuticals Inc	MIRM	3.53
Scholar Rock Holding Corp	SRRK	3.00
Vaxcyte Inc Ordinary Shares	PCVX	2.98
Beta Bionics Inc	BBNX	2.92
Celldex Therapeutics Inc	CLDX	2.89
Evolent Health Inc Class A	EVH	2.63

The benchmark used for this strategy is the NASDAQ Biotechnology Total Return Index. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical companies, and is a modifed market capitalization weighted index. Indices are reported to give a point of comparison only. An investor may not invest directly in an index. Benchmark data is provided by Morningstar and has not been independently verified.

The strategy is not necessarily appropriate for any particular client or investor. Accordingly, any reader of the attached description should not interpret the attached as investment advice. All investments bear a risk of loss, including the loss of principal that the investor should be prepared to bear. The use of any chart or graph in the attached is not intended to be viewed as a singular aid in determining investment strategy. Such visual aids are instead intended as a complement to other data, and like such other data, should be considered in light of consultations with professional investment tax and legal advisors. Past performance may not be indicative of future results. No current or prospective client should assume that the future performance of any specific investment, investment strategy (including investments and/or investment strategies recommended by the adviser), will be equal to past performance levels. Indices are reported to give a point of comparison only. An investor may not invest directly in an index. Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment will either be suitable or profitable for a client's investment portfolio.

**Partial period return (April 1, 2017 to December 31, 2017).*